{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:55:22Z","timestamp":1752231322958},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.mcna.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:37:52Z","timestamp":1715085472000},"page":"871-880","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Update on Therapies and Treatments in Women\u2019s Health"],"prefix":"10.1016","volume":"108","author":[{"given":"Christine","family":"Prifti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Merriam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Yecies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith M.E.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mcna.2024.03.007_bib1","first-page":"708","article-title":"Women\u2019s involvement in clinical trials: historical perspective and future implications","volume":"14","author":"Liu","year":"2016","journal-title":"Pharm Pract"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.007_bib2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women\u2019s health across the nation","volume":"96","author":"Gold","year":"2006","journal-title":"Am J Publ Health"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.007_bib3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/GME.0000000000001793","article-title":"Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden","volume":"28","author":"Nappi","year":"2021","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.007_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10382","key":"10.1016\/j.mcna.2024.03.007_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.007_bib6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT - pubMed","volume":"108","author":"Johnson","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.007_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.007_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatr"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.007_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am J Psychiatry"},{"issue":"23","key":"10.1016\/j.mcna.2024.03.007_bib10","first-page":"5625","article-title":"Estetrol: a new choice for contraception","volume":"10","author":"Fruzzetti","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.007_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.mcna.2024.03.007_bib12","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.conx.2020.100020","article-title":"A\u00a01-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4\u00a0mg using a 24\/4-day regimen","volume":"2","author":"Kimble","year":"2020","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.007_bib13","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1016\/S2214-109X(19)30265-7","article-title":"Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials","volume":"7","author":"Archer","year":"2019","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.mcna.2024.03.007_bib14","unstructured":"Anon. Phexxi Prescribing Information. No Year. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208352s002lbl.pdf."},{"key":"10.1016\/j.mcna.2024.03.007_bib15","doi-asserted-by":"crossref","first-page":"100031","DOI":"10.1016\/j.conx.2020.100031","article-title":"A\u00a0novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial","volume":"2","author":"Thomas","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.mcna.2024.03.007_bib16","unstructured":"Anon. Ortho Evra Label Supplement. No Year."},{"issue":"1","key":"10.1016\/j.mcna.2024.03.007_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13669-021-00321-4","article-title":"New Contraception update \u2014 annovera, phexxi, slynd, and twirla","volume":"11","author":"Baker","year":"2022","journal-title":"Current Obstetrics And Gynecology Reports"},{"key":"10.1016\/j.mcna.2024.03.007_bib18","unstructured":"Anon. Twirla vs Xulane: how do they compare? no year, Available at: https:\/\/www.drugs.com\/medical-answers\/twirla-xulane-compare-3554507\/. Accessed February 26, 2024."},{"issue":"3","key":"10.1016\/j.mcna.2024.03.007_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.007_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2022141","article-title":"Levonorgestrel vs. copper intrauterine devices for emergency contraception","volume":"384","author":"Turok","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.mcna.2024.03.007_bib21","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mcna.2024.03.007_bib22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.007_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American college of physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"issue":"7 Pt 2","key":"10.1016\/j.mcna.2024.03.007_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0002-9378(85)80003-X","article-title":"Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis","volume":"152","author":"Sobel","year":"1985","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.007_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100055","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis","volume":"1","author":"Sobel","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.007_bib26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.007_bib27","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious diseases society of America and the European society for microbiology and infectious diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.mcna.2024.03.007_bib28","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.007_bib29","first-page":"282","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.mcna.2024.03.007_bib30","article-title":"Methenamine hippurate for recurrent urinary tract infections","volume":"376","author":"Hoffmann","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.007_bib31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","article-title":"Sexual problems and distress in United States women: prevalence and correlates","volume":"112","author":"Shifren","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.007_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S109285292100002X","article-title":"The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women","volume":"27","author":"Pfaus","year":"2022","journal-title":"CNS Spectr"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.007_bib33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","article-title":"Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials","volume":"134","author":"Kingsberg","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.007_bib34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000003514","article-title":"Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder","volume":"134","author":"Simon","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.007_bib35","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1060028019899152","article-title":"Bremelanotide: new drug approved for treating hypoactive sexual desire disorder","volume":"54","author":"Mayer","year":"2020","journal-title":"Ann Pharmacother"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:11:04Z","timestamp":1722319864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025712524000245"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.007","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Therapies and Treatments in Women\u2019s Health","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}